GlaxoSmithKline Pharmaceuticals Limited

NSE: GLAXO

Healthcare Healthcare

₹2,495.4

-2.76%EOD · 19 Oct

GlaxoSmithKline Pharmaceuticals Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹42,274 Cr

52W Range

₹3121 / ₹2088

Volume

21K

51.8% delivery

1Y Return

-9.8%

P/E Ratio

40.7

P/B Ratio

19.2

ROE

49.1%

Debt / Equity

1.47

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
GlaxoSmithKline Pharmaceuticals Limited(this stock)	₹2,495.4	₹42,274 Cr	40.7	19.2	49.1%	2.26%
Divi's Laboratories LimitedDIVISLAB	₹9,087	₹2.41 L Cr	83.0	14.5	16.2%	0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,558.7	₹1.73 L Cr	72.8	18.4	17.0%	0.83%
Laurus Labs LimitedLAURUSLABS	₹2,069	₹1.12 L Cr	101.8	21.0	17.7%	0.12%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,113.9	₹1.11 L Cr	25.0	4.2	18.3%	0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹7,700	₹1.11 L Cr	54.3	12.0	21.5%	0.25%
Aurobindo Pharma LimitedAUROPHARMA	₹1,621.4	₹93,292 Cr	26.1	2.6	9.9%	0.00%
Mankind Pharma LimitedMANKIND	₹2,253.2	₹93,067 Cr	46.0	5.8	12.4%	0.00%
Max Healthcare Institute LimitedMAXHEALTH	₹830	₹80,785 Cr	56.7	7.7	14.3%	0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice

47/100

Composite score: 40% quality, 30% valuation, 30% momentum

QualityStrong · 75

ValuationWeak · 25

MomentumWeak · 30

High ROE (49.1%)

Technical Indicators

Full analysis · objective math, not advice

Returns

-2.8%

-1.4%

-10.9%

+0.5%

+1.7%

-9.8%

Weinstein Stage

Stage 3 — Topping (distribution)

RSI (14)

14 Oversold

Trend Template

4/7moderate

RS vs Nifty (3M)

+4.1pp

Moving Averages (price vs MA)

20-DMA

₹2693

below

50-DMA

₹2798

below

150-DMA

₹2525

below

200-DMA

₹2513

below

From 52W High

-20.0%

From 52W Low

+19.5%

Support (20D)

₹2473

Resistance (20D)

₹2987

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.